Medicare’s ESA Proposal Relies Too Much On Off-Label Data, Amgen Says
Executive Summary
CMS improperly applies safety data from off-label uses of erythropoiesis-stimulating agents to chemotherapy-induced anemia in its recent proposed national coverage determination on ESAs, Amgen maintains
You may also be interested in...
Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting
Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting
Senate Finance Committee Is Not SquWeemish About CMS Nominee
CMS Administrator-Nominee Kerry Weems faced no serious challenges during a July 25 confirmation hearing held by the Senate Finance Committee, with most of his comments focusing on a pledge to emphasize oversight of CMS programs